As most patients with type 2 diabetes are treated in the primary-care setting, the increasing utilization of SGLT2 inhibitors and GLP1 agonists by our primary-care colleagues will improve outcomes in people with type 2 diabetes on a population level. The clinical guidelines cautioned against treating people with type 2 diabetes with inadequate glycemic control with dipeptidyl peptidase-4 (DPP-4) inhibitors, saying that high-certainty evidence showed that adding a DPP-4 inhibitor does not reduce morbidity or all-cause mortality.
Our program specifically targets the metabolic challenges men face as they age: Combating age-related muscle loss while preserving lean mass Improving testosterone sensitivity through better insulin function Reducing visceral fat accumulation Supporting cardiovascular health and longevity Targeting Metabolic Syndrome: The Silent Aging Accelerator Metabolic syndromecharacterized by insulin resistance, abdominal obesity, high blood pressure, and dyslipidemiaaffects a significant portion of adults over 40
Modulation of Fecal Clostridiales Bacteria and Butyrate by Probiotic Intervention With Lactobacillus Paracasei DG Varies Among Healthy Adults
Results A total of 648,070 adult patients with T2D and NAFLD were identified, and patients were categorized into three different comparison groups based on their drug of interest
Naughton CK, Nangia AK, Agarwal A
